$2,321.99 general Payment -- Novartis Pharmaceuticals to Dr. David Kim

Novartis Pharmaceuticals pays Dermatologist David Kim $2,321.99 for services

This page provides a detailed analysis of a $2,321.99 general payment from Novartis Pharmaceuticals to Dr. David Kim. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$2,321.99
Payment Typegeneral
Payment NatureCompensation for services other than consulting
Pharmaceutical CompanyNovartis Pharmaceuticals
PhysicianDr. David Kim
NPI Number1707519586
Physician SpecialtyDermatology
LocationPeoria, IL
Date of Payment2024-11-12
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Novartis Pharmaceuticals made a $2.3K general payment to David Kim, a Dermatology specialist in Peoria, IL. The payment of $2,321.99 to Dr. David Kim from Novartis Pharmaceuticals is for services other than consulting. This payment was made on November 12, 2024, and is categorized as 'general'. Dr. Kim practices Dermatology in Peoria, IL.

Patient Guidance: What This Payment Means for You

This payment to your doctor is for services rendered and is publicly available information. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for services other than consulting are common in dermatology, but the specific amount and nature should be reviewed in the context of typical compensation for such services within the specialty.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the CMS Open Payments program, which requires manufacturers of drugs, medical devices, and biologics to report payments and other transfers of value made to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $2.3K payment for?

This was a general payment of $2.3K from Novartis Pharmaceuticals to David Kim, categorized as "Compensation for services other than consulting". The payment was reported under the Sunshine Act (CMS Open Payments).

Does David Kim accept pharmaceutical money?

Yes, David Kim received this $2.3K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view David Kim's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $2.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Dermatology?

To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about David Kim's relationship with Novartis Pharmaceuticals?

The payment amount is specific and itemized. This $2.3K general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Dermatology?

The payment type is 'general', suggesting it's not tied to a specific product or research.

What should patients do after learning about this payment?

This payment to your doctor is for services rendered and is publicly available information.

What else should I know about this general payment?

The payment nature clarifies it's for services rendered, not advisory roles.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.